Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com. For more information on Scilex Holding Company Sustainability Report, refer to www.scilexholding.com/investors/sustainability. For more information on ZTlido including Full Prescribing Information, refer to www.ztlido.com. For more information on ELYXYB, including Full Prescribing Information, refer to www.elyxyb.com. For more information on Gloperba, including Full Prescribing Information, refer to www.gloperba.com. PALO A ...